The potential role of trans-resveratrol/carboxymethylated (1.3/1.6)-β-d-glucan minimizing symptoms and improve healing after functional endoscopic sinus surgery

V. Frari, F. Capuano, A. Micera, F. Greco, F. Salvinelli

ENT Department, Campus Biomedico University, Rome, Italy. dr.f.capuano@gmail.com

---

• Pharmacology

OBJECTIVE: This study aims to evaluate the effect of trans-resveratrol/carboxymethylated (1.3/1.6)-β-d-glucan administered via nasal, after FESS, assessing nasal respiratory distress and nasal mucosa healing.

PATIENTS AND METHODS: We enrolled 70 patients, from March 2019 to February 2020, with chronic nasal obstruction not responding to medical therapy and candidates to endoscopic nasal surgery. Patients were divided in two non-randomized groups: group A treated with trans-resveratrol/carboxymethylated (1.3/1.6)-β-d-glucan administered via nasal, and group B treated with 0.9% nasal irrigation saline. Patients were clinically evaluated, in post-operative period, at 7 (T0), 15 (T1), and 30 days (T2) with fibroendoscopy. The CRS (chronic rhinosinusitis) questionnaire (Snot 20) was administrated at T0, T1, and T2. The findings were scored with respect to middle turbinate edema. In both Groups, the inferior turbinate’s medial aspect was scraped using a sterile disposable Rhino-probe mucosal curette (Arlington Scientific, Inc., Springville, UT, USA) at T0, T1, and T2.

RESULTS: Group A showed an improvement in Snot 20 in T1 and T2 both. The reduction of the mucosal edema and nasal secretion has been statistically significant in the Group A. A slight cell reduction was observed at T2 with respect to T1. This decreased pattern is more evident in nasal scraping from Group A. The appearance of epithelial cells at T2 of Group A is consistent with the reduction of inflammatory cells.

CONCLUSIONS: We can assert that in Group A it appears less evident the presence of edema, nasal congestion and crusts, resulting in a quick recover

Free PDF Download